Pieris Pharmaceuticals Ownership 2024 | Who Owns Pieris Pharmaceuticals Now?
Institutional Ownership
38.14%
Insider Ownership
6.97%
Retail Ownership
54.89%
Institutional Holders
39.00
Pieris Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BVF INC/IL | 20.83% | 0.10% | 20,609,863 | - | - | 3,775,727 | Mar 31, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | 8.87% | 0.42% | 8,779,162 | -996,687 | -10.20% | 1,608,342 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.45% | 0.00% | 1,429,588 | 364,581 | 34.23% | 262,000 | Mar 31, 2024 |
| BLACKROCK INC. | 1.05% | - | 1,037,639 | -108 | -0.01% | 190,096 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.98% | - | 967,235 | -222,652 | -18.71% | 177,197 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.97% | 0.00% | 962,358 | - | - | 175,000 | Mar 31, 2024 |
| VANGUARD GROUP INC | 0.92% | - | 907,390 | - | - | 166,234 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.78% | - | 772,784 | 11,340 | 1.49% | 141,620 | Mar 31, 2024 |
| CM MANAGEMENT, LLC | 0.58% | 0.09% | 575,000 | -175,000 | -23.33% | 105,340 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.25% | - | 243,592 | - | - | 44,626 | Mar 31, 2024 |
| STATE STREET CORP | 0.23% | - | 222,819 | - | - | 40,820 | Mar 31, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.22% | 0.00% | 220,800 | 110,600 | 100.36% | 40,451 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.21% | - | 211,745 | 45,060 | 27.03% | 38,792 | Mar 31, 2024 |
| SQUAREPOINT OPS LLC | 0.15% | - | 145,833 | 145,833 | 100.00% | 26,717 | Mar 31, 2024 |
| SUMMIT TRAIL ADVISORS, LLC | 0.14% | 0.00% | 140,000 | 140,000 | 100.00% | 25,648 | Mar 31, 2024 |
| CITIGROUP INC | 0.09% | - | 88,585 | - | - | 16,229 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.06% | 0.00% | 58,265 | 42,850 | 277.98% | 10,674 | Mar 31, 2024 |
| UBS GROUP AG | 0.05% | - | 51,994 | 45,714 | 727.93% | 9,515 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.04% | 0.00% | 42,742 | 34,626 | 426.64% | 7,822 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 0.03% | - | 33,900 | -700 | -2.02% | 6,210 | Mar 31, 2024 |
Pieris Pharmaceuticals's largest institutional shareholder is BVF INC/IL, holding 20.83% of the company's total share outstanding, currently valued at $3.78M. The top 10 institutional shareholders own together 36.68% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 8.87% | 0.42% | 8,779,162 | -996,687 | -10.20% | 1,608,342 | Mar 31, 2024 |
| BVF INC/IL | 20.83% | 0.10% | 20,609,863 | - | - | 3,775,727 | Mar 31, 2024 |
| CM MANAGEMENT, LLC | 0.58% | 0.09% | 575,000 | -175,000 | -23.33% | 105,340 | Mar 31, 2024 |
| NJ STATE EMPLOYEES DEFERRED COMPENSATION PLAN | 0.03% | 0.00% | 30,000 | - | - | 5,496 | Mar 31, 2024 |
| SUMMIT TRAIL ADVISORS, LLC | 0.14% | 0.00% | 140,000 | 140,000 | 100.00% | 25,648 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.97% | 0.00% | 962,358 | - | - | 175,000 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.02% | 0.00% | 20,756 | -18,933 | -47.70% | 3,802 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.45% | 0.00% | 1,429,588 | 364,581 | 34.23% | 262,000 | Mar 31, 2024 |
| HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 0.01% | 0.00% | 14,000 | - | - | 2,565 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.04% | 0.00% | 42,742 | 34,626 | 426.64% | 7,822 | Mar 31, 2024 |
| B. RILEY WEALTH ADVISORS, INC. | 0.02% | 0.00% | 17,000 | 17,000 | 100.00% | 5,066 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.06% | 0.00% | 58,265 | 42,850 | 277.98% | 10,674 | Mar 31, 2024 |
| TRUVESTMENTS CAPITAL LLC | 0.00% | 0.00% | 1,120 | - | - | 205,000 | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | 0.02% | 0.00% | 22,638 | 5 | 0.02% | 331,873 | Mar 31, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.22% | 0.00% | 220,800 | 110,600 | 100.36% | 40,451 | Mar 31, 2024 |
| SQUAREPOINT OPS LLC | 0.15% | - | 145,833 | 145,833 | 100.00% | 26,717 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.98% | - | 967,235 | -222,652 | -18.71% | 177,197 | Mar 31, 2024 |
| COMMERCE BANK | 0.02% | - | 20,000 | - | - | 3,664 | Mar 31, 2024 |
| KESTRA ADVISORY SERVICES, LLC | 0.02% | - | 17,500 | - | - | 3,206 | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | 0.03% | - | 25,700 | 18,970 | 281.87% | 4,708 | Mar 31, 2024 |
The largest Pieris Pharmaceuticals shareholder by % of total assets is LYNX1 CAPITAL MANAGEMENT LP. The company owns 8.78M shares of Pieris Pharmaceuticals (PIRS), representing 0.42% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1.45% | 0.00% | 1,429,588 | 364,581 | 34.23% | 262,000 | Mar 31, 2024 |
| SQUAREPOINT OPS LLC | 0.15% | - | 145,833 | 145,833 | 100.00% | 26,717 | Mar 31, 2024 |
| SUMMIT TRAIL ADVISORS, LLC | 0.14% | 0.00% | 140,000 | 140,000 | 100.00% | 25,648 | Mar 31, 2024 |
| PRUDENTIAL FINANCIAL INC | 0.22% | 0.00% | 220,800 | 110,600 | 100.36% | 40,451 | Mar 31, 2024 |
| UBS GROUP AG | 0.05% | - | 51,994 | 45,714 | 727.93% | 9,515 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.21% | - | 211,745 | 45,060 | 27.03% | 38,792 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.06% | 0.00% | 58,265 | 42,850 | 277.98% | 10,674 | Mar 31, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.04% | 0.00% | 42,742 | 34,626 | 426.64% | 7,822 | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | 0.03% | - | 25,700 | 18,970 | 281.87% | 4,708 | Mar 31, 2024 |
| B. RILEY WEALTH ADVISORS, INC. | 0.02% | 0.00% | 17,000 | 17,000 | 100.00% | 5,066 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.78% | - | 772,784 | 11,340 | 1.49% | 141,620 | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.01% | - | 6,145 | 6,000 | 4137.93% | 1,125,000 | Mar 31, 2024 |
| WELLS FARGO & COMPANY/MN | 0.01% | - | 5,573 | 812 | 17.06% | 1,021,000 | Mar 31, 2024 |
| JPMORGAN CHASE & CO | 0.00% | - | 1,989 | 18 | 0.91% | 365 | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | 0.02% | 0.00% | 22,638 | 5 | 0.02% | 331,873 | Mar 31, 2024 |
| MORGAN STANLEY | 0.01% | - | 6,856 | - | - | 1,256 | Mar 31, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.00% | - | 516 | - | - | 95,000 | Mar 31, 2024 |
| BARCLAYS PLC | 0.01% | - | 5,006 | - | - | 1,000 | Mar 31, 2024 |
| ALLWORTH FINANCIAL LP | 0.00% | - | 350 | - | - | 65,000 | Mar 31, 2024 |
| STATE STREET CORP | 0.23% | - | 222,819 | - | - | 40,820 | Mar 31, 2024 |
As of Mar 31 2024, Pieris Pharmaceuticals's largest institutional buyer is RENAISSANCE TECHNOLOGIES LLC. The company purchased 364.58K stocks of PIRS, valued at $262.00K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 8.87% | 0.42% | 8,779,162 | -996,687 | -10.20% | 1,608,342 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.98% | - | 967,235 | -222,652 | -18.71% | 177,197 | Mar 31, 2024 |
| CM MANAGEMENT, LLC | 0.58% | 0.09% | 575,000 | -175,000 | -23.33% | 105,340 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | - | - | - | -64,800 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -40,914 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -39,949 | -100.00% | - | Mar 31, 2024 |
| NORTHSTAR ASSET MANAGEMENT LLC /NJ/ | - | - | - | -39,065 | -100.00% | - | Mar 31, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | - | - | - | -20,300 | -100.00% | - | Mar 31, 2024 |
| XTX TOPCO LTD | 0.02% | 0.00% | 20,756 | -18,933 | -47.70% | 3,802 | Mar 31, 2024 |
| 1620 INVESTMENT ADVISORS, INC. | - | - | - | -4,421 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.00% | - | 200 | -4,100 | -95.35% | 37 | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -1,866 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 0.03% | - | 33,900 | -700 | -2.02% | 6,210 | Mar 31, 2024 |
| BLACKROCK INC. | 1.05% | - | 1,037,639 | -108 | -0.01% | 190,096 | Mar 31, 2024 |
| BVF INC/IL | 20.83% | 0.10% | 20,609,863 | - | - | 3,775,727 | Mar 31, 2024 |
| NJ STATE EMPLOYEES DEFERRED COMPENSATION PLAN | 0.03% | 0.00% | 30,000 | - | - | 5,496 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 0.97% | 0.00% | 962,358 | - | - | 175,000 | Mar 31, 2024 |
| HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 0.01% | 0.00% | 14,000 | - | - | 2,565 | Mar 31, 2024 |
| TRUVESTMENTS CAPITAL LLC | 0.00% | 0.00% | 1,120 | - | - | 205,000 | Mar 31, 2024 |
| COMMERCE BANK | 0.02% | - | 20,000 | - | - | 3,664 | Mar 31, 2024 |
As of Mar 31 2024, Pieris Pharmaceuticals's biggest institutional seller is LYNX1 CAPITAL MANAGEMENT LP. The company sold -1.00M shares of PIRS, valued at $1.61M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SQUAREPOINT OPS LLC | 0.15% | - | 145,833 | 145,833 | 100.00% | 26,717 | Mar 31, 2024 |
| SUMMIT TRAIL ADVISORS, LLC | 0.14% | 0.00% | 140,000 | 140,000 | 100.00% | 25,648 | Mar 31, 2024 |
Pieris Pharmaceuticals's largest new institutional shareholder by number of shares is SQUAREPOINT OPS LLC, purchased 145.83K shares, valued at $26.72K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | - | - | - | -64,800 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -40,914 | -100.00% | - | Mar 31, 2024 |
| BANK OF NEW YORK MELLON CORP | - | - | - | -39,949 | -100.00% | - | Mar 31, 2024 |
| NORTHSTAR ASSET MANAGEMENT LLC /NJ/ | - | - | - | -39,065 | -100.00% | - | Mar 31, 2024 |
| BAADER BANK AKTIENGESELLSCHAFT | - | - | - | -20,300 | -100.00% | - | Mar 31, 2024 |
| 1620 INVESTMENT ADVISORS, INC. | - | - | - | -4,421 | -100.00% | - | Mar 31, 2024 |
| RHUMBLINE ADVISERS | - | - | - | -1,866 | -100.00% | - | Mar 31, 2024 |
Pieris Pharmaceuticals's largest sold out institutional shareholder by shares sold is CITADEL ADVISORS LLC, sold -64.80K shares, valued at -, as of undefined.
Pieris Pharmaceuticals Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| TEKLA HEALTHCARE INVESTORS | 0.53% | 603,650 | - | - | Dec 31, 2023 |
| CORNERCAP GROUP OF FUNDS /VA/ | 0.48% | 34,753 | - | - | Sep 30, 2022 |
| TEKLA LIFE SCIENCES INVESTORS | 0.47% | 266,757 | - | - | Dec 31, 2023 |
| Tekla Healthcare Opportunities Fund | 0.07% | 161,014 | - | - | Dec 31, 2023 |
| BRIDGEWAY FUNDS INC | 0.05% | 116,500 | - | - | Dec 29, 2023 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.02% | 8,549 | - | - | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 3,495 | - | - | Dec 31, 2023 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.01% | 1,112,083 | - | - | Jan 31, 2024 |
| Fidelity Commonwealth Trust II | 0.01% | 81,145 | - | - | Aug 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 75,974 | - | - | Dec 31, 2023 |
| Federated Hermes MDT Series | 0.01% | 15,932 | - | - | Jan 31, 2024 |
| PFM Multi-Manager Series Trust | 0.01% | 4,360 | - | - | Dec 31, 2023 |
| VANGUARD INDEX FUNDS | 0.00% | 1,771,004 | 898,303 | 102.93% | Dec 31, 2023 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 16,596 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 722,472 | 7,564 | 1.06% | Feb 29, 2024 |
| AdvisorShares Trust | 0.00% | 8,336 | - | - | Dec 29, 2023 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 140,951 | - | - | Dec 31, 2023 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 7,116 | - | - | Dec 31, 2023 |
| MFS VARIABLE INSURANCE TRUST III | 0.00% | 26,480 | - | - | Dec 31, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 3,015 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 14,532 | - | - | Dec 31, 2023 |
| SCHWAB CAPITAL TRUST | 0.00% | 35,732 | - | - | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 24,798 | - | - | Dec 31, 2023 |
| SunAmerica Specialty Series | 0.00% | 409 | - | - | Apr 30, 2021 |
| Principal Exchange-Traded Funds | 0.00% | 7,557 | - | - | Mar 31, 2024 |
| HC CAPITAL TRUST | 0.00% | 18,161 | - | - | Dec 31, 2023 |
| Meeder Funds | 0.00% | 2,855 | - | - | Mar 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 38,277 | - | - | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 34,600 | - | - | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 529 | - | - | Dec 31, 2023 |
| Goldman Sachs ETF Trust | 0.00% | 14,916 | - | - | Feb 29, 2024 |
| PGIM ETF TRUST | 0.00% | 8,522 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 1,151 | - | - | Jan 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 9,300 | - | - | Dec 31, 2023 |
| FIDELITY SALEM STREET TRUST | 0.00% | 246,450 | - | - | Feb 29, 2024 |
| Direxion Shares ETF Trust | 0.00% | 13,524 | - | - | Jan 31, 2024 |
| VALIC Co I | 0.00% | 25,192 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 169,502 | - | - | Feb 29, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 6,677 | - | - | Dec 31, 2023 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 9,307 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 64,639 | - | - | Dec 31, 2023 |
| FLEXSHARES TRUST | 0.00% | 4,136 | - | - | Jan 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 15,212 | - | - | Jan 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,300 | - | - | Dec 29, 2023 |
| Voya MUTUAL FUNDS | 0.00% | 7,207 | - | - | Jan 31, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 300 | - | - | Dec 31, 2023 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 3,285 | - | - | Feb 29, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 29,063 | - | - | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 539 | - | - | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 26,815 | - | - | Dec 29, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 26,869 | - | - | Jan 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 52,400 | - | - | Dec 31, 2023 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 62,273 | - | - | Dec 31, 2023 |
| iShares U.S. ETF Trust | 0.00% | 1,408 | - | - | Jan 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 4,749 | - | - | Feb 29, 2024 |
| Brighthouse Funds Trust II | 0.00% | 24,572 | - | - | Dec 31, 2023 |
| EQ ADVISORS TRUST | 0.00% | 11,323 | - | - | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 22,404 | - | - | Dec 31, 2023 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 6,493 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 19,192 | - | - | Dec 31, 2023 |
| Advisors' Inner Circle Fund III | 0.00% | 29 | - | - | Jan 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 10,418 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 6,594 | - | - | Dec 31, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 488 | - | - | Jan 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 1,728 | - | - | Dec 31, 2023 |
| John Hancock Funds II | 0.00% | 9,354 | - | - | Feb 29, 2024 |
| BLACKROCK FUNDS | 0.00% | 4,255 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 12,800 | - | - | Feb 29, 2024 |
Pieris Pharmaceuticals's largest mutual fund holder by % of total assets is "TEKLA HEALTHCARE INVESTORS", owning 603.65K shares, compromising 0.53% of its total assets.
Pieris Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 39 | -13.33% |
| 31 Dec, 23 | 45 | 2.27% |
| 30 Sep, 23 | 44 | -8.33% |
| 30 Jun, 23 | 48 | -21.31% |
| 31 Mar, 23 | 61 | -4.69% |
| 31 Dec, 22 | 64 | 3.23% |
| 30 Sep, 22 | 62 | -4.62% |
| 30 Jun, 22 | 65 | -12.16% |
| 31 Mar, 22 | 74 | -9.76% |
| 31 Dec, 21 | 82 | -1.20% |
| 30 Sep, 21 | 83 | 1.22% |
| 30 Jun, 21 | 82 | 1.23% |
| 31 Mar, 21 | 81 | - |
| 31 Dec, 20 | 81 | -6.90% |
| 30 Sep, 20 | 87 | -5.43% |
| 30 Jun, 20 | 92 | -1.08% |
| 31 Mar, 20 | 93 | -6.06% |
| 31 Dec, 19 | 99 | 1.02% |
| 30 Sep, 19 | 98 | 8.89% |
| 30 Jun, 19 | 90 | -1.10% |
| 31 Mar, 19 | 91 | -5.21% |
| 31 Dec, 18 | 96 | -6.80% |
| 30 Sep, 18 | 103 | -8.85% |
| 30 Jun, 18 | 113 | -0.88% |
| 31 Mar, 18 | 114 | 29.55% |
| 31 Dec, 17 | 88 | 33.33% |
| 30 Sep, 17 | 66 | 37.50% |
| 30 Jun, 17 | 48 | 77.78% |
| 31 Mar, 17 | 27 | 12.50% |
| 31 Dec, 16 | 24 | -17.24% |
| 30 Sep, 16 | 29 | 11.54% |
| 30 Jun, 16 | 26 | 62.50% |
| 31 Mar, 16 | 16 | -11.11% |
| 31 Dec, 15 | 18 | 38.46% |
| 30 Sep, 15 | 13 | 8.33% |
| 30 Jun, 15 | 12 | - |
As of 31 Mar 24, 39 institutions are holding Pieris Pharmaceuticals's shares, representing a decrease of -13.33% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 37,730,023 | -1.78% |
| 31 Dec, 23 | 38,414,268 | -4.82% |
| 30 Sep, 23 | 40,359,937 | -16.98% |
| 30 Jun, 23 | 48,613,344 | 42.01% |
| 31 Mar, 23 | 34,231,602 | -3.32% |
| 31 Dec, 22 | 35,408,934 | 1.49% |
| 30 Sep, 22 | 34,889,090 | -6.50% |
| 30 Jun, 22 | 37,316,031 | -0.66% |
| 31 Mar, 22 | 37,565,259 | 5.89% |
| 31 Dec, 21 | 35,475,699 | 13.10% |
| 30 Sep, 21 | 31,365,838 | 18.51% |
| 30 Jun, 21 | 26,467,529 | -17.50% |
| 31 Mar, 21 | 32,083,520 | -3.65% |
| 31 Dec, 20 | 33,299,243 | 0.60% |
| 30 Sep, 20 | 33,101,880 | -3.51% |
| 30 Jun, 20 | 34,307,178 | -6.56% |
| 31 Mar, 20 | 36,714,112 | 3.80% |
| 31 Dec, 19 | 35,369,671 | 25.50% |
| 30 Sep, 19 | 28,182,166 | 3.74% |
| 30 Jun, 19 | 27,165,787 | -7.42% |
| 31 Mar, 19 | 29,343,810 | -15.45% |
| 31 Dec, 18 | 34,707,053 | -1.77% |
| 30 Sep, 18 | 35,331,663 | 0.97% |
| 30 Jun, 18 | 34,993,498 | 3.09% |
| 31 Mar, 18 | 33,945,324 | 43.79% |
| 31 Dec, 17 | 23,607,001 | 4.48% |
| 30 Sep, 17 | 22,595,587 | 0.37% |
| 30 Jun, 17 | 22,512,980 | 15.95% |
| 31 Mar, 17 | 19,415,637 | -3.70% |
| 31 Dec, 16 | 20,162,440 | -1.52% |
| 30 Sep, 16 | 20,474,081 | 3.87% |
| 30 Jun, 16 | 19,712,020 | 13.19% |
| 31 Mar, 16 | 17,415,286 | -1.55% |
| 31 Dec, 15 | 17,690,231 | -4.28% |
| 30 Sep, 15 | 18,480,416 | 9.93% |
| 30 Jun, 15 | 16,810,691 | - |
Pieris Pharmaceuticals (PIRS) has 37.73M shares outstanding as of 31 Mar 24, down -1.78% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 38.14% | 2.53% |
| 31 Dec, 23 | 38.86% | 1.83% |
| 30 Sep, 23 | 46.05% | 1.08% |
| 30 Jun, 23 | 65.24% | 3.09% |
| 31 Mar, 23 | 45.94% | 2.02% |
| 31 Dec, 22 | 47.74% | 2.17% |
| 30 Sep, 22 | 46.90% | 1.85% |
| 30 Jun, 22 | 50.34% | 1.94% |
| 31 Mar, 22 | 50.96% | 1.69% |
| 31 Dec, 21 | 54.96% | 2.56% |
| 30 Sep, 21 | 46.31% | 2.53% |
| 30 Jun, 21 | 42.76% | 1.32% |
| 31 Mar, 21 | 56.99% | 1.53% |
| 31 Dec, 20 | 61.12% | 1.65% |
| 30 Sep, 20 | 60.92% | 1.42% |
| 30 Jun, 20 | 65.51% | 1.48% |
| 31 Mar, 20 | 66.50% | 1.36% |
| 31 Dec, 19 | 69.87% | 2.14% |
| 30 Sep, 19 | 57.10% | 1.87% |
| 30 Jun, 19 | 55.21% | 1.66% |
| 31 Mar, 19 | 57.68% | 1.35% |
| 31 Dec, 18 | 65.39% | 1.53% |
| 30 Sep, 18 | 65.32% | 1.55% |
| 30 Jun, 18 | 64.82% | 1.41% |
| 31 Mar, 18 | 67.83% | 3.05% |
| 31 Dec, 17 | 47.17% | 1.82% |
| 30 Sep, 17 | 50.91% | 1.89% |
| 30 Jun, 17 | 51.86% | 2.55% |
| 31 Mar, 17 | 45.09% | 1.93% |
| 31 Dec, 16 | 48.34% | 2.14% |
| 30 Sep, 16 | 47.54% | 2.04% |
| 30 Jun, 16 | 48.24% | 2.52% |
| 31 Mar, 16 | 43.72% | 2.21% |
| 31 Dec, 15 | 44.46% | 1.97% |
| 30 Sep, 15 | 47.52% | 1.46% |
| 30 Jun, 15 | 57.12% | - |
As of 31 Mar 24, Pieris Pharmaceuticals is held by 38.14% institutional shareholders, representing a 2.53% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 14 | 16.67% |
| 31 Dec, 23 | 12 | -33.33% |
| 30 Sep, 23 | 18 | 38.46% |
| 30 Jun, 23 | 13 | -27.78% |
| 31 Mar, 23 | 18 | -14.29% |
| 31 Dec, 22 | 21 | 16.67% |
| 30 Sep, 22 | 18 | -30.77% |
| 30 Jun, 22 | 26 | -23.53% |
| 31 Mar, 22 | 34 | -15.00% |
| 31 Dec, 21 | 40 | 2.56% |
| 30 Sep, 21 | 39 | 11.43% |
| 30 Jun, 21 | 35 | 25.00% |
| 31 Mar, 21 | 28 | -22.22% |
| 31 Dec, 20 | 36 | 16.13% |
| 30 Sep, 20 | 31 | -29.55% |
| 30 Jun, 20 | 44 | -2.22% |
| 31 Mar, 20 | 45 | -13.46% |
| 31 Dec, 19 | 52 | 13.04% |
| 30 Sep, 19 | 46 | 21.05% |
| 30 Jun, 19 | 38 | 31.03% |
| 31 Mar, 19 | 29 | -43.14% |
| 31 Dec, 18 | 51 | 2.00% |
| 30 Sep, 18 | 50 | -20.63% |
| 30 Jun, 18 | 63 | -27.59% |
| 31 Mar, 18 | 87 | 58.18% |
| 31 Dec, 17 | 55 | 34.15% |
| 30 Sep, 17 | 41 | 10.81% |
| 30 Jun, 17 | 37 | 131.25% |
| 31 Mar, 17 | 16 | 77.78% |
| 31 Dec, 16 | 9 | -40.00% |
| 30 Sep, 16 | 15 | - |
| 30 Jun, 16 | 15 | 87.50% |
| 31 Mar, 16 | 8 | -11.11% |
| 31 Dec, 15 | 9 | - |
| 30 Sep, 15 | 9 | -25.00% |
| 30 Jun, 15 | 12 | - |
14 institutional shareholders have increased their position in PIRS stock as of 31 Mar 24 compared to 12 in the previous quarter (a 16.67% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 6 | -33.33% |
| 31 Dec, 23 | 9 | 125.00% |
| 30 Sep, 23 | 4 | -76.47% |
| 30 Jun, 23 | 17 | -10.53% |
| 31 Mar, 23 | 19 | -13.64% |
| 31 Dec, 22 | 22 | 10.00% |
| 30 Sep, 22 | 20 | -13.04% |
| 30 Jun, 22 | 23 | 21.05% |
| 31 Mar, 22 | 19 | -9.52% |
| 31 Dec, 21 | 21 | 23.53% |
| 30 Sep, 21 | 17 | -43.33% |
| 30 Jun, 21 | 30 | 3.45% |
| 31 Mar, 21 | 29 | 45.00% |
| 31 Dec, 20 | 20 | -41.18% |
| 30 Sep, 20 | 34 | 41.67% |
| 30 Jun, 20 | 24 | -22.58% |
| 31 Mar, 20 | 31 | 3.33% |
| 31 Dec, 19 | 30 | - |
| 30 Sep, 19 | 30 | -9.09% |
| 30 Jun, 19 | 33 | 10.00% |
| 31 Mar, 19 | 30 | 11.11% |
| 31 Dec, 18 | 27 | -6.90% |
| 30 Sep, 18 | 29 | 3.57% |
| 30 Jun, 18 | 28 | 154.55% |
| 31 Mar, 18 | 11 | -31.25% |
| 31 Dec, 17 | 16 | 60.00% |
| 30 Sep, 17 | 10 | 25.00% |
| 30 Jun, 17 | 8 | 100.00% |
| 31 Mar, 17 | 4 | 33.33% |
| 31 Dec, 16 | 3 | -25.00% |
| 30 Sep, 16 | 4 | -20.00% |
| 30 Jun, 16 | 5 | 150.00% |
| 31 Mar, 16 | 2 | -50.00% |
| 31 Dec, 15 | 4 | 300.00% |
| 30 Sep, 15 | 1 | - |
| 30 Jun, 15 | - | - |
6 institutional shareholders have reduced their position in PIRS stock as of 31 Mar 24 compared to 9 in the previous quarter (a -33.33% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 39 | -13.33% | 37,730,023 | -1.78% | 38.14% | 2.53% | 14 | 16.67% | 6 | -33.33% |
| 31 Dec, 23 | 45 | 2.27% | 38,414,268 | -4.82% | 38.86% | 1.83% | 12 | -33.33% | 9 | 125.00% |
| 30 Sep, 23 | 44 | -8.33% | 40,359,937 | -16.98% | 46.05% | 1.08% | 18 | 38.46% | 4 | -76.47% |
| 30 Jun, 23 | 48 | -21.31% | 48,613,344 | 42.01% | 65.24% | 3.09% | 13 | -27.78% | 17 | -10.53% |
| 31 Mar, 23 | 61 | -4.69% | 34,231,602 | -3.32% | 45.94% | 2.02% | 18 | -14.29% | 19 | -13.64% |
| 31 Dec, 22 | 64 | 3.23% | 35,408,934 | 1.49% | 47.74% | 2.17% | 21 | 16.67% | 22 | 10.00% |
| 30 Sep, 22 | 62 | -4.62% | 34,889,090 | -6.50% | 46.90% | 1.85% | 18 | -30.77% | 20 | -13.04% |
| 30 Jun, 22 | 65 | -12.16% | 37,316,031 | -0.66% | 50.34% | 1.94% | 26 | -23.53% | 23 | 21.05% |
| 31 Mar, 22 | 74 | -9.76% | 37,565,259 | 5.89% | 50.96% | 1.69% | 34 | -15.00% | 19 | -9.52% |
| 31 Dec, 21 | 82 | -1.20% | 35,475,699 | 13.10% | 54.96% | 2.56% | 40 | 2.56% | 21 | 23.53% |
| 30 Sep, 21 | 83 | 1.22% | 31,365,838 | 18.51% | 46.31% | 2.53% | 39 | 11.43% | 17 | -43.33% |
| 30 Jun, 21 | 82 | 1.23% | 26,467,529 | -17.50% | 42.76% | 1.32% | 35 | 25.00% | 30 | 3.45% |
| 31 Mar, 21 | 81 | - | 32,083,520 | -3.65% | 56.99% | 1.53% | 28 | -22.22% | 29 | 45.00% |
| 31 Dec, 20 | 81 | -6.90% | 33,299,243 | 0.60% | 61.12% | 1.65% | 36 | 16.13% | 20 | -41.18% |
| 30 Sep, 20 | 87 | -5.43% | 33,101,880 | -3.51% | 60.92% | 1.42% | 31 | -29.55% | 34 | 41.67% |
| 30 Jun, 20 | 92 | -1.08% | 34,307,178 | -6.56% | 65.51% | 1.48% | 44 | -2.22% | 24 | -22.58% |
| 31 Mar, 20 | 93 | -6.06% | 36,714,112 | 3.80% | 66.50% | 1.36% | 45 | -13.46% | 31 | 3.33% |
| 31 Dec, 19 | 99 | 1.02% | 35,369,671 | 25.50% | 69.87% | 2.14% | 52 | 13.04% | 30 | - |
| 30 Sep, 19 | 98 | 8.89% | 28,182,166 | 3.74% | 57.10% | 1.87% | 46 | 21.05% | 30 | -9.09% |
| 30 Jun, 19 | 90 | -1.10% | 27,165,787 | -7.42% | 55.21% | 1.66% | 38 | 31.03% | 33 | 10.00% |
| 31 Mar, 19 | 91 | -5.21% | 29,343,810 | -15.45% | 57.68% | 1.35% | 29 | -43.14% | 30 | 11.11% |
| 31 Dec, 18 | 96 | -6.80% | 34,707,053 | -1.77% | 65.39% | 1.53% | 51 | 2.00% | 27 | -6.90% |
| 30 Sep, 18 | 103 | -8.85% | 35,331,663 | 0.97% | 65.32% | 1.55% | 50 | -20.63% | 29 | 3.57% |
| 30 Jun, 18 | 113 | -0.88% | 34,993,498 | 3.09% | 64.82% | 1.41% | 63 | -27.59% | 28 | 154.55% |
| 31 Mar, 18 | 114 | 29.55% | 33,945,324 | 43.79% | 67.83% | 3.05% | 87 | 58.18% | 11 | -31.25% |
| 31 Dec, 17 | 88 | 33.33% | 23,607,001 | 4.48% | 47.17% | 1.82% | 55 | 34.15% | 16 | 60.00% |
| 30 Sep, 17 | 66 | 37.50% | 22,595,587 | 0.37% | 50.91% | 1.89% | 41 | 10.81% | 10 | 25.00% |
| 30 Jun, 17 | 48 | 77.78% | 22,512,980 | 15.95% | 51.86% | 2.55% | 37 | 131.25% | 8 | 100.00% |
| 31 Mar, 17 | 27 | 12.50% | 19,415,637 | -3.70% | 45.09% | 1.93% | 16 | 77.78% | 4 | 33.33% |
| 31 Dec, 16 | 24 | -17.24% | 20,162,440 | -1.52% | 48.34% | 2.14% | 9 | -40.00% | 3 | -25.00% |
| 30 Sep, 16 | 29 | 11.54% | 20,474,081 | 3.87% | 47.54% | 2.04% | 15 | - | 4 | -20.00% |
| 30 Jun, 16 | 26 | 62.50% | 19,712,020 | 13.19% | 48.24% | 2.52% | 15 | 87.50% | 5 | 150.00% |
| 31 Mar, 16 | 16 | -11.11% | 17,415,286 | -1.55% | 43.72% | 2.21% | 8 | -11.11% | 2 | -50.00% |
| 31 Dec, 15 | 18 | 38.46% | 17,690,231 | -4.28% | 44.46% | 1.97% | 9 | - | 4 | 300.00% |
| 30 Sep, 15 | 13 | 8.33% | 18,480,416 | 9.93% | 47.52% | 1.46% | 9 | -25.00% | 1 | - |
| 30 Jun, 15 | 12 | - | 16,810,691 | - | 57.12% | - | 12 | - | - | - |
Pieris Pharmaceuticals Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Pieris Pharmaceuticals's stock was made by BVF PARTNERS L P/IL on May 22 2023, selling - shares at - per share (valued at -). The last insider buy of PIRS was made by KIRITSY CHRISTOPHER P on May 30 2023, buying 10,000 shares at $0.85 per share (worth $8.50K).
Pieris Pharmaceuticals Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2023 | 8 | 9 | 88.89% |
| Q1 2023 | 5 | - | - |
| Q2 2022 | 8 | - | - |
| Q1 2022 | 6 | - | - |
| Q4 2021 | - | 6 | - |
| Q3 2021 | 2 | 11 | 18.18% |
| Q2 2021 | 7 | - | - |
| Q1 2021 | 3 | - | - |
| Q3 2020 | - | 1 | - |
| Q2 2020 | 9 | - | - |
| Q1 2020 | 12 | - | - |
| Q4 2019 | 1 | - | - |
| Q3 2019 | 3 | 13 | 23.08% |
| Q2 2019 | 1 | - | - |
| Q1 2019 | 15 | 3 | 500.00% |
| Q4 2018 | 3 | 6 | 50.00% |
| Q3 2018 | 2 | - | - |
| Q2 2018 | 3 | 2 | 150.00% |
| Q1 2018 | 15 | 6 | 250.00% |
| Q4 2017 | 29 | 14 | 207.14% |
8 total buy trades, and 9 total sell trades (buy/sell ratio of 0.89%) were made by Pieris Pharmaceuticals's insiders, as of Q2 2023.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2023 | 1 | - | - |
| Q1 2023 | - | - | - |
| Q2 2022 | 1 | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | - | - |
| Q3 2021 | - | 2 | - |
| Q2 2021 | - | - | - |
| Q1 2021 | - | - | - |
| Q3 2020 | - | 1 | - |
| Q2 2020 | - | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | - | - | - |
| Q3 2019 | - | 3 | - |
| Q2 2019 | - | - | - |
| Q1 2019 | - | - | - |
| Q4 2018 | - | - | - |
| Q3 2018 | 1 | - | - |
| Q2 2018 | 1 | 2 | 50.00% |
| Q1 2018 | - | 4 | - |
| Q4 2017 | - | 2 | - |
As of Q2 2023, Insider owners conducted 1 open market buy trades and 0 open market sell trades of Pieris Pharmaceuticals's stocks.
Pieris Pharmaceuticals Peer Ownership
| Ticker | Company |
|---|---|
| CKPT | Checkpoint Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| CRVS | Corvus Pharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ADAP | Adaptimmune Therapeutics plc |
| AGEN | Agenus Inc. |
| PDSB | PDS Biotechnology Corporation |
| CUE | Cue Biopharma, Inc. |
| AFMD | Affimed N.V. |
| ADCT | ADC Therapeutics SA |
| MDNA | Medicenna Therapeutics Corp. |
| ACHL | Achilles Therapeutics plc |
| LPTX | Leap Therapeutics, Inc. |
PIRS Ownership FAQ
Who Owns Pieris Pharmaceuticals?
Pieris Pharmaceuticals is owned by institutional shareholders (38.14%), insiders (6.97%), and public (54.89%). The largest institutional shareholder of Pieris Pharmaceuticals is BVF INC/IL (20.83% of total shares) and the top mutual fund owner is TEKLA HEALTHCARE INVESTORS (0.53% of total shares).
Who are the major institutional shareholders of Pieris Pharmaceuticals?
Pieris Pharmaceuticals's major institutional shareholders are BVF INC/IL, LYNX1 CAPITAL MANAGEMENT LP, RENAISSANCE TECHNOLOGIES LLC, BLACKROCK INC., and CITADEL ADVISORS LLC. The top five shareholders own together 33.18% of the company's share outstanding.
How many Pieris Pharmaceuticals shareholders are there?
As of Mar 2024, there are 39 institutional shareholders of Pieris Pharmaceuticals.
What percentage of Pieris Pharmaceuticals is owned by BVF INC/IL?
BVF INC/IL owns 20.61M shares of Pieris Pharmaceuticals, representing 20.83% of the company's total shares outstanding, valued at $3.78M (as of Mar 2024).
What percentage of Pieris Pharmaceuticals is owned by LYNX1 CAPITAL MANAGEMENT LP?
As of Mar 2024, LYNX1 CAPITAL MANAGEMENT LP holds 8.78M shares of Pieris Pharmaceuticals (PIRS), compromising 8.87% of the company, valued at $1.61M.
What percentage of Pieris Pharmaceuticals is owned by RENAISSANCE TECHNOLOGIES LLC?
RENAISSANCE TECHNOLOGIES LLC is the third largest holder of Pieris Pharmaceuticals. The company owns 1.43M of the company's shares outstanding (worth $262K).